Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety.

Literature DB >> 22977402

Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety.

Abstract

Entities: Chemical

Year: 2010 PMID： 22977402 PMCID： PMC3411146

Source DB: PubMed Journal: CADTH Technol Overv ISSN： 1203-9012

× No keyword cloud information.

19 in total

1. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

Authors: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Eva Muehlhofer; Christoph Dierig; Frank Misselwitz; Peter Kälebo
Journal: Circulation Date: 2006-11-20 Impact factor: 29.690

2. Direct thrombin inhibitors.

Authors: Marcello Di Nisio; Saskia Middeldorp; Harry R Büller
Journal: N Engl J Med Date: 2005-09-08 Impact factor: 91.245

3. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Authors: A G G Turpie; W D Fisher; K A Bauer; L M Kwong; M W Irwin; P Kälebo; F Misselwitz; M Gent
Journal: J Thromb Haemost Date: 2005-11 Impact factor: 5.824

4. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Authors: B I Eriksson; O E Dahl; H R Büller; R Hettiarachchi; N Rosencher; M-L Bravo; L Ahnfelt; F Piovella; J Stangier; P Kälebo; P Reilly
Journal: J Thromb Haemost Date: 2005-01 Impact factor: 5.824

5. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.

Authors: B I Eriksson; L Borris; O E Dahl; S Haas; M V Huisman; A K Kakkar; F Misselwitz; P Kälebo
Journal: J Thromb Haemost Date: 2006-01 Impact factor: 5.824

Review 6. Diagnostic assessment of deep vein thrombosis and pulmonary embolism.

Authors: Geno Merli
Journal: Am J Med Date: 2005-08 Impact factor: 4.965

7. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors: B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal: J Thromb Haemost Date: 2007-11 Impact factor: 5.824

8. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Authors: Bengt I Eriksson; Ola E Dahl; Nadia Rosencher; Andreas A Kurth; C Niek van Dijk; Simon P Frostick; Martin H Prins; Rohan Hettiarachchi; Stefan Hantel; Janet Schnee; Harry R Büller
Journal: Lancet Date: 2007-09-15 Impact factor: 79.321